Myoinositol: The New Challenge in Treatment of Polycystic Ovary (PCOS) with Infertility
Inas A Yahea, Ahmed G Elsayed, Laila M Elgendy and Patrick Choueiry
Introduction: Polycystic ovarian syndrome (PCOS) is the most prevalent endocrine disorder in women
of reproductive age, affecting approximately 6–15% of them and associated with chronic anovulation.
Myoinositol is an insulin-sensitizing agent ingested with food and actively synthetized in the liver and
brain.
Aim of the work: To study the effect of Myoinositol and Metformin in the treatment of PCOS with
infertility in the area of Tobruk - Libya.
Methods: The study group included 800 selected cases of PCOS with infertility and insulin resistance,
diagnosed and treated in the Gynecology and Obstetrics department of Tobruk Medical Center, Libya,
from January 2018 to January 2022. Patients were randomly distributed into two groups: Group 1 (n
= 400) in which Myoinositol 2000 mg was given daily by taking two tablets of Celine® (Laboratoires
Surveal) after breakfast and another two tablets after dinner and Metformin 850 mg taken only during
lunch. Group 2 (n = 400) in which only Metformin 850 mg was taken during lunch. The individual
treatment period was 8 months. All patients were followed up by ultrasound to see the progress of
ovulation.
Results: The mean age of the patients in group 1 is 29 years (range, 18–40 years) and that in group
2 is 32 years (range, 22–42 years). Mean pre-study serum glucose level is 193 mg/dl in group 1 and
208 mg/dl in group 2. Mean pre-study Insulin level is 284 mIU/L in group 1 and 295 mIU/L in group 2.
There was a highly significant improvement in serum glucose level, serum insulin level, acne, hirsutism,
body weight, menstrual cycle regularity, follicles diameter and pregnancy in the group treated with a
combination of Myoinositol and Metformin.
Conclusion: Our results show that the use of Myoinositol and Metformin is a useful combination
treatment of polycystic ovary patients with infertility showing improvement of laboratory, clinical and
ovulation with subsequent pregnancy.
